Skip to content
OpenCapital
Get started

Immunome IMNM Business Segments — Other Direct Research And Development

Similar metrics at other companies

Alumis Inc. logo
ALMSSingle Reportable — Other Research And Development Expense
$2.37M+3.2%
Celldex Therapeutics logo
CLDXSingle Reportable — Other Research And Development Expense
$4.88M+48.9%
Ocular Therapeutix logo
OCULSingle Reportable — Research And Development Unallocated Expenses All Other Costs
$1.81M-44.4%
Travere Therapeutics, Inc. logo
TVTXReportable Segment — Other research and development
$4.84M+9.2%
Alumis Inc. logo
ALMSSingle Reportable — Research And Development Expense
$81.54M-15.6%
Lantheus Holdings logo
LNTHReportable — Other Research And Development Expense
$27.59M-1.1%

Other financials

Income statement

See full
Revenue--100%
Operating income-$59.3M-32.9%
Net income-$53.8M-29.3%
EPS (diluted)-$0.48+7.7%

Balance sheet

See full
Cash & equivalents$582.7M+126%
Total debt$3.7M-22.6%
Total equity$588.7M+91.7%
Total assets$619.8M+80.9%

Cash flow

See full
Operating cash flow-$58.6M-10.5%
CapEx$3.0M-18.1%
Free cash flow-$61.6M-8.7%

Valuation

See full
Market cap$2.19B+323%
Enterprise value$1.61B+470%
P/S545.2×+498×

Profitability

See full
Operating margin-5,947.9%-12,002pp
Net margin-5,593.8%-11,284pp
FCF margin-5,118.9%-8,601pp

Returns & leverage

See full
Return on equity-50.1%-10.8pp
Debt / equity0×0.0×
Current ratio21.7×+11.2×

Where this comes from

Reported directly by Immunome in its filing.

Tagged under the XBRL concept imnm:OtherDirectResearchAndDevelopment.

The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunome's business segments — other direct research and development.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immunome's business segments — other direct research and development?
Immunome (IMNM) reported business segments — other direct research and development of $9.97M in Q1 2026.
How has Immunome's business segments — other direct research and development changed year-over-year?
Immunome's business segments — other direct research and development increased by 113.4% year-over-year, from $4.67M to $9.97M.
What does business segments — other direct research and development mean?
Includes miscellaneous direct costs related to research and development activities that are not classified under specific program-level or indirect categories. This often captures ancillary lab expenses, specialized equipment maintenance, or project-specific overheads. Tracking this provides visibility into the operational complexity and non-programmatic spending required to sustain R&D efforts.